Thus, HGF treatment restored growth inhibition of epidermal growth factor receptor (EGFR)-mutant lung carcinoma cells by the EGFR tyrosine kinase inhibitor gefitinib [96] and that of BRAF-mutant melanoma cells by the BRAF inhibitors PLX4720 and PLX4032 [11,83]. Here, EGFR is linked to lung carcinoma.